• Target：
• ORAOV1

• Gene Name：
• ORAOV1

• Protein Name：
• Oral cancer-overexpressed protein 1

• Human Gene Id：
• 220064

• Human Swiss Prot No：
• Q8WV07

• Mouse Swiss Prot No：
• Q8CH62

• Immunogen：
• The antiserum was produced against synthesized peptide derived from human ORAV1. AA range:81-130

• Specificity：
• ORAOV1 Polyclonal Antibody detects endogenous levels of ORAOV1 protein.

• Formulation：
• Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

• Source：
• Polyclonal, Rabbit,IgG

• Dilution：
• WB 1:500 - 1:2000. IHC 1:100 - 1:300. IF 1:200 - 1:1000. ELISA: 1:10000. Not yet tested in other applications.

• Purification：
• The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

• Concentration：
• 1 mg/ml

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• ORAOV1;TAOS1;Oral cancer-overexpressed protein 1;Tumor-amplified and overexpressed sequence 1

• Observed Band(KD)：
• 15kD

• Background：
• miscellaneous:Amplified and overexpressed in oral cancer cells.,similarity:Belongs to the ORAOV1 family.,tissue specificity:Widely expressed. Highly expressed in placenta, kidney and skeletal muscle.,

• Function：
• miscellaneous:Amplified and overexpressed in oral cancer cells.,similarity:Belongs to the ORAOV1 family.,tissue specificity:Widely expressed. Highly expressed in placenta, kidney and skeletal muscle.,

• Subcellular Location：
• Nucleus .

• Expression：
• Widely expressed. Highly expressed in placenta, kidney and skeletal muscle.

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs